(Q31881233)

English

Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

0 references

author name string

Zegels B

1

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Eastell R

2

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Russell RG

3

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Ethgen D

4

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Roumagnac I

5

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Collette J

6

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Reginster JY

7

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

language of work or name

1 reference

based on heuristic

publication date

1 January 2001

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

108-112

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900410-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900410-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900410-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900410-5

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900410-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900410-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900410-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900410-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pamidronate: an unrecognized problem in gastrointestinal tolerability

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900410-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900410-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900410-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Bisphosphonates: pharmacology, mechanisms of action and clinical uses

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900410-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained response to intravenous alendronate in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900410-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S8756-3282(00)00410-5

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31881233&oldid=1606341990"